{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:27Z","timestamp":1788957387563,"version":"build-2803163510"},"reference-count":15,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2022,11,30]]},"DOI":"10.7883\/yoken.jjid.2022.092","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T22:10:10Z","timestamp":1656540610000},"page":"608-611","source":"Crossref","is-referenced-by-count":12,"title":["Casirivimab\/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy"],"prefix":"10.7883","volume":"75","author":[{"given":"Hiroyuki","family":"Nagai","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"},{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sakai-Tagawa","sequence":"additional","affiliation":[{"name":"Department of Virology, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Yamayoshi","sequence":"additional","affiliation":[{"name":"Department of Virology, The Institute of Medical Science, The University of Tokyo, Japan"},{"name":"The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kiso","sequence":"additional","affiliation":[{"name":"Department of Virology, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyotaka","family":"Kawamata","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"},{"name":"Center for Antibody and Vaccine Therapy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Department of Virology, The Institute of Medical Science, The University of Tokyo, Japan"},{"name":"The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Japan"},{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"},{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"},{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. Brosseau LM, Escand\u00f3n K, Ulrich AK, et al. SARS-CoV-2 dose, infection, and disease outcomes for COVID-19 - a review. Clin Infect Dis. 2021;ciab903."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yasuda H, Mori Y, Chiba A, et al. Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk. 2021;21:e810-e816.","DOI":"10.1016\/j.clml.2021.07.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell-depleted patient with protracted coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73:e4020-e4024.","DOI":"10.1093\/cid\/ciaa1637"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kaila V, Sirkeoja S, Blomqvist S, et al. SARS-CoV-2 late shedding may be infectious between immunocompromised hosts. Infect Dis (Lond). 2021;53:880-882.","DOI":"10.1080\/23744235.2021.1939891"},{"key":"5","unstructured":"5. Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3:e419-e426."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ollila TA, Lu S, Masel R, et al. Antibody response to COVID-19 vaccination in adults with hematologic malignant disease. JAMA Oncol. 2021;7:1714-1716.","DOI":"10.1001\/jamaoncol.2021.4381"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sachdeva M, Dhingra S. Obinutuzumab. A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia. Int J Appl Basic Med Res. 2015;5:54-57.","DOI":"10.4103\/2229-516X.149245"},{"key":"8","unstructured":"8. U.S. Food and Drug Administration (FDA). GAZYVA rescribing information. Available at <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125486s017s018lbl.pdf>. Accessed November 17, 2021."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27:1990-2001.","DOI":"10.1038\/s41591-021-01507-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238-251.","DOI":"10.1056\/NEJMoa2035002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Corey L, Beyrer C, Cohen MS, et al. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385:562-566.","DOI":"10.1056\/NEJMsb2104756"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014-1018.","DOI":"10.1126\/science.abd0831"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gandhi S, Klein J, Robertson AJ, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022;13:1547.","DOI":"10.1038\/s41467-022-29104-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chiba S, Kiso M, Nakajima N, et al. Co-administration of favipiravir and the remdesivir metabolite GS-441524 effectively reduces SARS-CoV-2 replication in the lungs of the Syrian hamster model. mBio. 2022;13:e0304421.","DOI":"10.1128\/mbio.03044-21"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med. 2022;386:995-998.","DOI":"10.1056\/NEJMc2119407"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/75\/6\/75_JJID.2022.092\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:01:31Z","timestamp":1715317291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/75\/6\/75_JJID.2022.092\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2022.092","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"article-number":"JJID.2022.092"}}